22.21
+1.09(+5.16%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
108
First IPO Date
February 05, 2021
| Name | Title | Pay | Year Born |
| Mr. Berndt Axel Edvard Modig CPA, M.B.A. | Co-Founder, Chief Executive Officer & Executive Director | 649,766 | 1959 |
| Ms. Annick Deschoolmeester | Chief Human Resources Officer | 0 | 1973 |
| Dr. Peng Lu M.D., Ph.D. | Chief Medical Officer | 0 | 1978 |
| Mr. David W. Nassif J.D. | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | 0 | 1954 |
| Dr. Anne A. Lesage Ph.D. | Chief Early Development Officer | 0 | 1961 |
| Maryann Cimino | Director of Corporate Relations | 0 | N/A |
| Mr. Wim Souverijns Ph.D. | Chief Commercial Officer | 0 | 1971 |
| Dr. Stefan Abele Ph.D. | Chief Technology Operations Officer | 0 | 1970 |
| Ms. Anna Nijdam M.Sc., R.A. | Head of Strategic Finance & Principal Accounting Officer | 0 | 1981 |
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
